cronos group glp-1 receptor agonist weight management diabetes treatments agonism: a transformative approach for managing type-2 and obesity | Saudi Pharmaceutical Journal Evolution of GLP‐1 Receptor Agonists

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist

GLP-1 RAs have demonstrated benefits in coronary artery disease, heart failure, blood pressure, and atrial fibrillation irrespective of type 2 diabetes mellitus status, with new possible applications in peripheral arterial disease

Welcome to Hospitalogy, a newsletter breaking down healthcare finance, M&A, and strategy twice weekly

Discover the novel mechanism of action of Empagliflozin in managing type 2 diabetes and other benefits, such as reduced cardiovascular risks, potential weight loss, and lowered blood pressure.

This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction

Ease your GLP-1 journey with Side Effect Relief